The QMN Weekly Bulletin

Alexion Faces Potential $25 Million Charge From Recall

Dec. 20, 2013
Alexion’s recall and replacement of vials of its rare disease drug Soliris could cost the company between $10 and $25 million in the fourth quarter, the drugmaker says in a recent SEC filing. The recall and replacement was prompted by the presence of visible particles observed as part of Alexion’s periodic testing of retained samples.
Drug GMP Report